INVESTORS' RIGHTS AGREEMENT

                                                              Execution Version

                           INVESTORS' RIGHTS AGREEMENT

      This  Investors'  Rights  Agreement,  dated as of December  22, 2006 (the
"Agreement"),  is made and entered into by and among Quest Midstream  Partners,
L.P., a Delaware limited  partnership  ("Company"),  Quest Midstream GP, LLC, a
Delaware  limited  liability  company  ("GP"),  Quest Resource  Corporation,  a
Nevada corporation  ("QRC"),  Alerian Opportunity Partners IV, L.P., a Delaware
limited  partnership  ("Alerian"),  Swank  MLP  Convergence  Fund,  LP, a Texas
limited  partnership  ("Swank  MLP Fund"),  Swank  Investment  Partners,  LP, a
Texas limited  partnership  ("SIP"),  The Cushing MLP Opportunity Fund I, LP, a
Delaware limited  partnership  ("Cushing MLP Fund"),  The Cushing GP Strategies
Fund,  LP, a Delaware  limited  partnership  ("Cushing GP Fund",  together with
Swank  MLP  Fund,  SIP  and  Cushing  MLP  Fund,  "Swank"),   Tortoise  Capital
Resources   Corporation,   a  Maryland   corporation   ("Tortoise"),   Huizenga
Opportunity  Partners,  LP, a  Delaware  limited  partnership  ("HOP")  and HCM
Energy Holdings,  LLC, an Illinois  limited  liability  company  (together with
HOP,  "Huizenga").   Alerian,   Swank,  Tortoise  and  Huizenga  are  sometimes
referred  to  herein   individually  as  "Investor"  and  collectively  as  the
"Investors."

      WHEREAS,  the  Company,  GP,  QRC  and the  Investors  are  parties  to a
Purchase  Agreement of even date herewith (the "Purchase  Agreement")  pursuant
to which the  Investors  acquired  certain of the Company's  Common Units,  and
Alerian and Swank acquired certain of the GP's Member Interests.

      NOW,    THEREFORE,    in   consideration   of   the   mutual   covenants,
representations,  warranties  and  agreements  contained  herein,  and of other
good and  valuable  consideration,  the  receipt and  sufficiency  of which are
hereby  acknowledged,  and intending to be legally  bound  hereby,  the parties
hereto hereby agree as follows:

      1.  Definitions  and  Interpretations.  Unless  otherwise  provided to the
contrary  in this  Agreement,  capitalized  terms  in this  Agreement  have  the
meanings set forth in Section 1.1 of Exhibit A. Unless expressly provided to the
contrary in this  Agreement,  this Agreement  shall be interpreted in accordance
with the provisions set forth in Section 1.2 of Exhibit A.

      2. Board Representation.
         --------------------

            (a) Designation of Board Member. For the period hereafter indicated,
      Alerian  and Swank  will each have a  separate  and  independent  right to
      designate  one (1)  natural  person  to serve as a member  of the Board of
      Directors  of GP.  QRC will  have the  right to  designate  the  remaining
      members of the Board of  Directors  of GP. In order to effect  this right,
      QRC (or its Affiliates  that own Member  Interests)  shall vote the Member
      Interests  in GP owned by it in a manner so as to cause and  maintain  the
      election of the persons so designated. Swank's right to designate a member
      of the Board of  Directors  shall  terminate  upon the  completion  by the
      Company of an IPO. In  addition,  such right to  designate a member of the
      Board of  Directors  shall  terminate  as to Alerian or Swank (or both) at
      such time (either before or after  completion by the Company of an IPO) as
      such  designating  person  ceases to own at least five percent (5%) of the
      Common

<PAGE>

      Units (measured on a fully-diluted basis that assumes that all outstanding
      warrants,  options, rights and securities that are at any time exercisable
      for or convertible  into Common Units have been so exercised or converted)
      held by Persons other that QRC or its Affiliates.

            (b) Expansion of Board. The parties currently contemplate that until
      the completion by the Company of an IPO, the Board of Directors of GP will
      consist of six (6) persons.  During the period prior to  completion  of an
      IPO that  Alerian or Swank has the right to designate a person to serve on
      the Board of Directors of GP, such designating person shall have the right
      to maintain  its  proportionate  Board  representation  in the event of an
      expansion  of the number of members of the Board of  Directors;  provided,
      however,   that  such   right  to   maintain   the   proportionate   Board
      representation will terminate upon completion by the Company of an IPO.

            (c) Replacement. In the event of the resignation,  death, removal or
      disqualification  of a person designated by QRC, Alerian or Swank to serve
      on the Board of Directors, as set forth above, the appropriate designating
      party or parties  shall  promptly  designate  a new member of the Board of
      Directors,  and after written notice of the  designation has been given by
      such  designating  party or parties to the other parties,  each of QRC and
      the Investors shall vote its Member Interests to elect such nominee to the
      Board of Directors.

            (d)  Removal.  The  appropriate  designating  party or  parties  may
      specify  that  any  person  designated  by it to  serve  on the  Board  of
      Directors  shall be  removed  at any time and from  time to time,  with or
      without cause.

            (e)  Indemnification  and  Insurance.  So long as either  Alerian or
      Swank has a right to designate a Director  pursuant to this Section 2, the
      GP shall maintain director and officer insurance  reasonably  satisfactory
      to Alerian and Swank, as the case may be.

      3. Obligation to Participate in Certain Sales.
         ------------------------------------------

            (a) Approved Sale.  Subject to the provisions of subsection 3(c), if
      an IPO has not been completed by the Company by the second  anniversary of
      the  Closing  Date,  then  until such time as an IPO is  completed  by the
      Company,  a Majority of Investors may elect by written notice (a "Required
      Sale  Notice")  to  require  the GP to effect a Sale of the  Company  that
      satisfies  the  conditions  indicated in Section 3(b) below (an  "Approved
      Sale").  Upon  receipt of a  Required  Sale  Notice  and if a Majority  of
      Investors  do not accept the GP Offer  Price,  the GP shall  undertake  to
      effect a Sale of the Company as promptly as commercially reasonable with a
      view to  maximizing  the aggregate  consideration  to be received for such
      sale;  provided,  however,  that all  parties  shall work in good faith to
      complete an Approved  Sale within 180 days after  receipt of the  Required
      Sale  Notice by the GP.  Upon  receipt of a Required  Sale Notice and if a
      Majority of  Investors  do not accept the GP Offer  Price,  the  Conflicts
      Committee of the Board shall engage an investment banking firm of national
      reputation to seek  Qualifying  Offers (as defined  below) for an Approved
      Sale.  The  Conflicts  Committee  of the  Board  shall  have  the  primary
      responsibility for negotiating the terms of any potential Qualifying Offer
      and shall present to the  Investors all offers  received for a Sale of the
      Company that satisfy the  conditions  for an Approved Sale (a  "Qualifying
      Offer").  Subject to Section  3(c),  if a

                                       2
<PAGE>

      Majority of Investors agrees to accept a Qualifying Offer, then all of the
      parties  hereto  shall (i) consent  to,  vote for and raise no  objections
      against  the  Qualifying  Offer  or the  process  pursuant  to  which  the
      Qualifying Offer was arranged,  (ii) waive any dissenters',  appraisal and
      similar rights with respect thereto,  and (iii) if the Qualifying Offer is
      a sale of the Partnership Interests agree to sell all of their Partnership
      Interests  and  Member  Interests  on  the  terms  and  conditions  of the
      Qualifying  Offer.  The  parties  hereto  shall  take  all  necessary  and
      desirable  actions in  connection  with the  consummation  of any Approved
      Sale, including,  without limitation, the execution of such agreements and
      instruments  and other  actions  reasonably  necessary  to (A) provide the
      representations,  warranties,  indemnities,  covenants, conditions, escrow
      agreements and  provisions and agreements  relating to such Approved Sale,
      and (B)  effectuate  the  allocation  and  distribution  of the  aggregate
      consideration upon the Approved Sale as set forth below.

            (b) Conditions.  Unless  otherwise agreed to by all of the Investors
      and the GP, an Approved Sale must satisfy all of the following conditions:

                  (i) the Approved Sale must be solely for cash consideration;

                  (ii) no purchaser  may be an Affiliate or Related Party of any
            Investor  unless consent thereto is given by GP, which consent shall
            not be unreasonably withheld;

                  (iii)  upon  the   consummation  of  the  Approved  Sale,  the
            aggregate  net proceeds  from the Approved  Sale (x) if the Approved
            Sale is a sale of  substantially  all of the assets of the  Company,
            shall be  distributed  to and among the  Partners and the Members in
            accordance  with the provisions of Section 6.4(c) of the Partnership
            Agreement  and  Section  15.02  of  the  Limited  Liability  Company
            Agreement  and  (y) if the  Approved  Sale  is a sale  of all of the
            Partnership  Interests and Member  Interests,  shall be  apportioned
            among the Partners  and the  Members,  in the same amounts as if the
            full amount of such net proceeds are to be  distributed to and among
            the Partners and the Members,  in accordance  with the provisions of
            Section 6.4(c) of the Partnership Agreement and Section 15.02 of the
            Limited   Liability   Company  Agreement  (and  assuming  the  prior
            satisfaction of the debts and obligations of the Company and GP);

                  (iv) No  party  shall  receive  direct  remuneration  from the
            purchaser  in an  Approved  Sale other than the net  proceeds  to be
            apportioned among the parties in accordance with Section  3(b)(iii),
            including  but  not  limited  to  remuneration  for  non-competition
            provisions or other similar arrangements.

                  (v) All expenses of the Approved Sale (other than the fees and
            expenses of any counsel or other advisors retained by the Investors,
            which  fees  and  expenses  shall  be  paid  by the  Investors,  but
            including  any  investment  banking  firm  fees  and the fees of any
            counsel   retained  by  the  Conflicts   Committee  in  finding  and
            negotiating  Qualifying  Offers)  shall be paid by the  Company  and
            shall  reduce the net  proceeds  distributable  pursuant  to Section
            3(b)(iii); and


                                       3
<PAGE>

                  (vi) In the event that the  parties  are  required to make any
            covenants,  representations  or indemnities  in connection  with the
            Approved  Sale,  then,  (A)  each  party  shall  severally  (and not
            jointly) make the Fundamental Warranties solely with respect to such
            party,   and  (B)  other  than  with  respect  to  the   Fundamental
            Warranties,  the  obligations  and  liabilities  of the Partners and
            Members  participating  in the Approved  Sale shall first be limited
            solely to any escrow fund that may be established in connection with
            such  transaction  (with the escrow  funded solely from the purchase
            price  proceeds  and  which  escrow  fund  shall not be in an amount
            greater  than  10% of  the  aggregate  purchase  price  paid  by the
            purchaser(s) in such  transaction),  and second,  if and only if the
            escrow  fund  is for  10%  of  the  aggregate  purchase  price,  any
            obligations   and   liabilities   of  the   Partners   and   Members
            participating in the Approved Sale (other than any claims for fraud,
            willful misconduct or bad faith by a Partner or Member,  which shall
            be the  responsibility  of such  Partner or  Member)  shall be borne
            solely by QRC.  The  escrowed  funds shall be released no later than
            one (1) year following the closing of the Approved  Sale,  provided,
            however,  that to the  extent  there are  pending  claims or demands
            relating to any breach,  misrepresentation  or indemnity against the
            escrow fund, an amount of the escrowed funds equal to such aggregate
            claims or demands will be retained until such claims and demands are
            finally  resolved.  Upon  distribution of the escrowed funds (or any
            part thereof), each Partner and Member shall receive their "pro rata
            share" of the distributed funds.

      As used in this  Section  3, a party's  "pro rata  share"  shall mean the
ratio of (A) the total  consideration  to be  received by such party in or as a
result of an Approved  Sale, to (B) the total  consideration  to be received by
all  Partners and Members as a result of such  Approved  Sale  (including  upon
dissolution of the Company and GP following an Approved Sale).

            (c) GP Right of First Offer/Refusal.
                -------------------------------

                  (i) Upon receipt by the GP of a Required  Sale Notice,  the GP
            shall  have the  right of first  offer  (before  the  Approved  Sale
            process proceeds) to indicate the price, if any, that the GP (or its
            designee)  would pay in connection with a Sale of the Company to the
            GP (or its designee)  (the "GP Offer  Price").  If a Majority of the
            Investors agrees to accept the GP Offer price, then such offer shall
            constitute an approved  Qualifying  Offer  pursuant to Section 3(a),
            and the transaction  shall proceed as an Approved Sale to the GP (or
            its  designee)  in  accordance  with the terms of Sections  3(a) and
            3(b), it being  understood that in such event QRC and its Affiliates
            will  not be  sellers  of  their  Partnership  Interests  or  Member
            Interests  (and the  purchase  price  paid will be net of the amount
            attributable to the Partnership  Interests and Member Interests held
            by such Persons,  based on the total GP Offer Price). The GP (or its
            designee)  shall have thirty  (30) days after  receipt of a Required
            Sale Notice to indicate the  applicable  GP Offer Price,  if any, or
            such right shall be deemed to have been  waived;  and the  Investors
            shall,  within  fifteen days after receipt of notice of the GP Offer
            Price,  notify the GP ("Election to Sell Notice") of the  acceptance
            or rejection (by a Majority of the Investors) of the GP Offer Price.


                                       4
<PAGE>

                  (ii) If a Majority of  Investors  accepts a  Qualifying  Offer
            (other than an offer  arising  from the GP's right of first offer in
            clause (i) above),  the GP (or its designee) will have the right and
            option (but not an obligation)  (the "GP Right of First Refusal") to
            purchase all of the Common Units and Member  Interests then owned by
            the Investors,  exercisable by notice to the Investors ("Election to
            Purchase  Notice")  given no later than ten (10) business days after
            the GP is  notified  that a Majority  of  Investors  has  accepted a
            Qualifying  Offer;  provide  however,  that  the GP  Right  of First
            Refusal shall not apply with respect to such Qualifying Offer if (A)
            the GP (or its  designee)  did not  indicate a GP Offer Price in the
            allowed time  period,  (B) such  Qualifying  Offer is for a purchase
            price for a Sale of the Company that is 115% or more of the GP Offer
            Price,  or (C) if the GP Offer Price was less than $100  million (as
            an enterprise  value for a Sale of the Company,  including the value
            of the  Partnership  Interests and Member  Interests held by QRC and
            its Affiliates)  and such  Qualifying  Offer is for a purchase price
            for a Sale of the  Company  that  is  105%  or more of the GP  Offer
            Price.

                  (iii) If GP (or its  designee)  purchases the Common Units and
            Member  Interests owned by the Investors  (either pursuant to clause
            (i) or (ii) above),  the purchase  price to be paid to the Investors
            will be an amount  equal to the  amount  each  Investor  would  have
            received in  accordance  with the  provisions of Section 3(b) above,
            had the  parties  completed  the  Qualifying  Offer  approved by the
            Majority of Investors on the terms and at the price indicated in the
            Qualifying  Offer.  Any  Common  Units  and  Member  Interests  sold
            hereunder  by  the  Investors  to GP  (or  its  designee)  shall  be
            transferred free and clear of all liens and encumbrances (other than
            encumbrances  set  forth  in  the  Partnership  Agreement  or  under
            applicable  securities laws).  Closing of the purchase of the Common
            Units  and  Member  Interests  by GP  (or  its  designee)  from  the
            Investors shall occur within one hundred twenty (120) days following
            delivery  of the  Election  to Sell  Notice or  Election to Purchase
            Notice, as the case may be. Until such closing,  the Investors shall
            continue to receive all distributions on the Common Units and Member
            Interests as provided pursuant to the Partnership  Agreement and the
            Limited  Liability  Company  Agreement.   At  the  closing  of  such
            purchase,  GP (or its designee)  shall deliver the purchase price by
            wire  transfer of  immediately  available  funds to an account to be
            designated by each  Investor,  and each  Investor  shall execute and
            deliver such  assignments,  bills of sale, and other  documents,  as
            reasonably requested by an in form and substance satisfactory to, GP
            (or its designee).

      4. Limitations on Subsequent Sales of Common Units.
         -----------------------------------------------

            (a) Minimum Issue Price.  Without the written  consent of a Majority
      of Investors,  the Company will not issue or sell any Common Units (or any
      securities  exercisable  for or convertible  into Common Units) at a price
      less than  115% of the Issue  Price  except  for (i) Class A  Subordinated
      Units issued to QRC or its  Affiliates  in exchange for  additional  asset
      contributions;  provided that such Class A  Subordinated  Units may not be
      issued at a price less than the Issue Price and provided that the purchase
      price for such  additional  asset  contributions  shall be approved by the
      Investor



                                       5
<PAGE>

      Representatives and the Conflicts Committee, (ii) Common Units (or options
      therefor)  issued  pursuant to the Long-Term  Incentive Plan or employment
      agreements to which the Company (or its controlled Affiliates) is a party,
      or (iii) Common Units issued pursuant to an IPO.

            (b)  Adjustment  to Issue Price.  If the Company at any time or from
      time  to  time  after  the